SCHEMBL3236002

SCHEMBL3236002

CC1CCN(C(=O)c2ccc(C(=O)NCc3ccc(Cl)cc3)cc2)C1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.58
SMN1; SMN2 Q16637 4/20 0.56
MAPT P10636 3/20 0.56
HPGD P15428 2/20 0.56
ALDH1A1 P00352 1/20 0.56
LMNA P02545 1/20 0.56
HSD11B1 P28845 1/20 0.56
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C19 P33261 1/20 0.53
RAB9A P51151 1/20 0.53
POLB P06746 2/20 0.53
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA9 Q16790 1/20 0.53
HTT P42858 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3237604 0.93 GRM5 (0.68) GRM5SMN1; SMN2MAPTHPGDALDH1A1
SCHEMBL3236009 0.86 GRM5 (0.64) GRM5SMN1; SMN2MAPTHPGDALDH1A1
SCHEMBL12918516 0.85 GRM5 (0.71) GRM5SMN1; SMN2MAPTHPGDALDH1A1
SCHEMBL3379917 0.83 GRM5 (0.57) GRM5SMN1; SMN2HPGDALDH1A1LMNA
SCHEMBL3263478 0.83 HPGD (0.60) GRM5SMN1; SMN2MAPTHPGDALDH1A1
SCHEMBL3235633 0.82 KMT2A (0.61) GRM5SMN1; SMN2MAPTHPGDALDH1A1
SCHEMBL20394972 0.81 GAA (0.63) GRM5SMN1; SMN2MAPTHPGDALDH1A1
SCHEMBL3259879 0.80 MAPT (0.70) SMN1; SMN2MAPTHPGDALDH1A1LMNA
SCHEMBL3237608 0.80 GRM5 (0.75) GRM5SMN1; SMN2MAPTHPGDALDH1A1
SCHEMBL3264723 0.79 ALDH1A1 (0.55) MAPTHPGDALDH1A1LMNAHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 GRM5 1140/4885SMN1; SMN2 3175/4885MAPT 3110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.